Sofinnova Partners Closes €650M ($750M) Capital XI, to Back Early-Stage Healthcare Companies

Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan, led by Antoine Papiernik, Henrijette Richter, Graziano Seghezzi, Anta Gkelou, Maina Bhaman, Karl Naegler, and others, has announced the close of its latest flagship fund, Sofinnova Capital XI, at €650 million ($750 million), greatly exceeding its initial target.

Sofinnova Capital XI will support a new wave of biopharma and medtech companies developing breakthrough solutions for urgent, unmet clinical needs.

Sofinnova Capital XI drew strong backing from a global group of blue-chip institutional investors, including sovereign wealth funds, major pharmaceutical companies, insurers, foundations, family offices, and other corporates. Commitments spanned Europe, North America, Asia, and the Middle East, with most capital coming from returning LPs alongside a notable cohort of new top-tier investors, underscoring sustained confidence in Sofinnova’s strategy and track record.

Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, described the raise as a pivotal milestone that expands the firm’s ability to pursue early-stage opportunities and strengthens its collaborative, science-driven investment model. The fund will support visionary founders and advance breakthrough innovations in science and medicine toward global patient impact.

He noted that securing this level of commitment in a volatile fundraising environment underscores the resilience of Sofinnova’s strategy and the continued confidence of its investors.

Sofinnova Capital XI is already deploying capital into several portfolio companies and will continue backing early-stage biotech and medtech ventures across Europe and North America, taking part in both initial and follow-on rounds.